Journal of Nuclear Medicine: 62 (10)

October 1, 2021; Volume 62,Issue 10

Cover image

FEATURED ARTICLE

A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors. Wenjia Zhu et al. See page 1398.

In this issue

Issue highlights

A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of ⁶⁸Ga-NODAGA-LM3 and ⁶⁸Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules

First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a ⁶⁸Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04
Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region
Diagnostic Evaluation of Pulmonary Embolism During the COVID-19 Pandemic
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

More...

Main menu

User menu

Search

Table of Contents

Cover image

In this issue

Issue highlights

Jump to